VitalConnect获得 1亿美元投资，用于扩展患者监测产品-动脉网

VitalConnect reels in $100m investment to expand patient monitoring products

Medical Device Network 等信源发布 2025-02-20 14:41



可切换为仅中文







VitalConnect specialises in cardiac-related patient care and was founded in 2011. Image credit: Johan Swanepoel

VitalConnect 专注于心脏相关的患者护理，成立于 2011 年。图片来源：Johan Swanepoel

via Shutterstock.

通过Shutterstock。

Patient monitoring company VitalConnect has raised $100m through a combination of equity and debt capital.

患者监测公司VitalConnect通过股权和债务资本的组合筹集了1亿美元。

The US company stated that it would use the funds to expand the commercial presence of its biosensor and remote patient monitoring offerings.

这家美国公司表示，将利用这笔资金扩大其生物传感器和远程患者监测产品的商业影响力。

Go deeper with GlobalData

通过GlobalData深入了解

Reports

报告

Laryngoscope Blades and Handles Market Size (Value, Volume, ASP) by...

喉镜片和手柄市场规模（价值、数量、平均售价）按...

Reports

报告

Cloud in Healthcare: Remote Continuous Monitoring Devices

医疗云：远程连续监测设备

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多信息

VitalConnect’s portfolio includes VitalPatch RTM, a wearable biosensor for the remote monitoring of up to 21 different cardiac arrhythmias and vital signs including respiratory rate and body temperature; and VitalConnect Solution, a platform for the remote monitoring of key vital signs for home use or in hospital settings..

VitalConnect的产品组合包括VitalPatch RTM，这是一种可穿戴生物传感器，用于远程监测多达21种不同的心律失常和生命体征，包括呼吸频率和体温；以及VitalConnect解决方案，这是一个用于家庭或医院环境中远程监测关键生命体征的平台。

The equity financing portion of the funding tranche was led by new investor Ally Bridge Group, with participation from existing VitalConnect investors, including EW Healthcare Partners, MVM and Revelation Partners. Trinity Capital provided the debt financing.

本轮融资的股权融资部分由新投资者Ally Bridge Group领投，现有VitalConnect投资者参与，包括EW Healthcare Partners、MVM和Revelation Partners。Trinity Capital提供了债务融资。

VitalConnect CEO Peter Van Haur commented: “Our best-in-class proprietary biosensor, coupled with the live streaming of eight vital signs and biometric parameters over a seven-day wear period, sets VitalConnect apart from the competition.

VitalConnect首席执行官彼得·范霍尔评论道：“我们一流的专有生物传感器，加上在七天的佩戴期内实时传输八个生命体征和生物识别参数，使VitalConnect在竞争中脱颖而出。

“Additionally, we continue to develop our in-patient remote patient monitoring offering in close collaboration with some of the leading healthcare facilities in the US.

“此外，我们继续与美国一些领先的医疗机构密切合作，开发我们的住院患者远程监护服务。"

In line with the financing round, Ally Bridge vice president Steven Plachtyna is joining VitalConnect’s board.

与这轮融资一致，Ally Bridge副总裁史蒂文·普拉赫蒂纳将加入VitalConnect的董事会。

Plachtyna commented: “Ally Bridge Group is pleased to lead this financing to accelerate VitalConnect’s growth, appreciating the company’s highly differentiated strengths in addressing conditions that significantly affect the quality of life for millions of patients.”

Plachtyna评论道：“Ally Bridge Group很高兴能够主导此次融资，以加速VitalConnect的增长，我们非常欣赏该公司在解决严重影响数百万患者生活质量的疾病方面所具备的高度差异化优势。”

In 2020, VitalConnect gained emergency use authorisation (EUA) status from the US Food and Drug Administration (FDA) for VitalPatch as

2020年，VitalConnect的VitalPatch获得了美国食品药品监督管理局（FDA）的紧急使用授权（EUA）状态，

part of the response to the Covid-19 pandemic

对新冠疫情大流行的部分应对措施

, given the biosensor’s ability to monitor the potential heart-related side effects related to Covid-19 treatments.

，鉴于生物传感器能够监测与新冠治疗相关的心脏潜在副作用。

GlobalData analysis indicates that the latest financing round brings VitalConnect’s total funds raised since 2013 to

GlobalData分析显示，最新的融资使VitalConnect自2013年以来的总融资额达到

around $272m.

大约 2.72 亿美元。

The overall global patient monitoring market is growing at a CAGR of 2.30% and will be worth around $15.1m by 2033, as per GlobalData analysis.